Cardio Diagnostics Holdings (CDIO) Total Current Liabilities (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Total Current Liabilities of $491443.0 for Q1 2026, down 18.75% sequentially from $604839.0 in Q4 2025, and down 9.1% YoY from $540616.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Total Current Liabilities (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Total Current Liabilities for 6 years, with the latest figure at $491443.0 in Q1 2026.
- Quarterly Total Current Liabilities fell 9.1% year-over-year to $491443.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $491443.0 (down 9.1% YoY) and the FY2025 annual result came in at $604839.0, down 4.25% from the prior year.
- Total Current Liabilities slipped to $491443.0 in Q1 2026 per CDIO's latest filing, from $604839.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $3.0 million in Q3 2023 and troughed at $180542.0 in Q1 2022.
- A 5-year average of $746188.6 and a median of $540616.0 in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities soared 1465.3% in 2022, then plunged 89.55% in 2024.
- Over 5 years, Total Current Liabilities stood at $1.9 million in 2022, then sank by 56.82% to $841142.0 in 2023, then declined by 24.9% to $631695.0 in 2024, then slipped by 4.25% to $604839.0 in 2025, then slipped by 18.75% to $491443.0 in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $491443.0, $604839.0, and $398448.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | 359,197.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 359,197.00 |
| Mar 31, 2026 | 491,443.00 |
| Dec 31, 2025 | 604,839.00 |
| Sep 30, 2025 | 398,448.00 |
| Jun 30, 2025 | 369,597.00 |
| Mar 31, 2025 | 540,616.00 |
| Dec 31, 2024 | 631,695.00 |
| Sep 30, 2024 | 308,679.00 |
| Jun 30, 2024 | 376,096.00 |
| Mar 31, 2024 | 685,672.00 |
| Dec 31, 2023 | 841,142.00 |
| Sep 30, 2023 | 2.96 Mn |
| Dec 31, 2022 | 1.95 Mn |
| Sep 30, 2022 | 631,748.00 |
| Jun 30, 2022 | 229,434.00 |
| Mar 31, 2022 | 180,542.00 |
| Dec 31, 2021 | 124,434.00 |